Antidepressant dose, age, and the risk of deliberate self-harm

JAMA Internal Medicine

Volumn 174, Issue 6, 2014, Pages 899-909

  Miller, Matthew ^a   Swanson, Sonja A ^a   Azrael, Deborah ^a   Pate, Virginia ^b   Stürmer, Til ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; ADULT; ARTICLE; ATTRIBUTABLE RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GROUPS BY AGE; HAZARD RATIO; HEALTH CARE UTILIZATION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; RISK ASSESSMENT; SEX RATIO; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT DURATION; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHILD; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; SELF-INJURIOUS BEHAVIOR; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84902213510     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.1053     Document Type: Article

References (56)

1. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339. (Pubitemid 43345358)
2. Stone M, Laughren T, JonesML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339: b2880.
3. Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research. The importance of restriction. JAMA. 2010;304(8):897-898.
4. Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(1):64-74.
5. Patten SB. Confounding by severity and indication in observational studies of antidepressant effectiveness. Can J Clin Pharmacol. 2008;15(2):e367-e371.
6. Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol. 2005;60(5):519-525. (Pubitemid 41532452)
7. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J AmGeriatr Soc. 1999;47(6): 749-754. (Pubitemid 29266647)
8. Walker AM. Confounding by indication. Epidemiology. 1996;7(4):335-336.
9. RayWA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. (Pubitemid 37323253)
10. BrookhartMA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(6)(suppl):S114-S120.
11. Stürmer T, Jonsson Funk M, Poole C, Brookhart MA. Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology. 2011;22(3):298-301.
12. Jick H, Kaye JA, Jick SS. Antidepressants an. The risk of suicidal behaviors. JAMA. 2004;292(3): 338-343.
13. Martinez C, Assimes TL,Mines D, Dell'aniello S, Suissa S. Use of venlafaxine compared with other antidepressants an. The risk of sudden cardiac death or near death: a nested case-control study. BMJ. 2010;340:c249.
14. Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment an. The risk of fatal and non-fatal self-harm in first episode depression: nested case-control study. BMJ. 2005;330(7488): 389.
15. Rubino A, Roskell N, Tennis P,Mines D,Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ. 2007;334(7587): 242.
16. Schneeweiss S, Patrick AR, Solomon DH, et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics. 2010;125(5):876-888.
17. Schneeweiss S, Patrick AR, Solomon DH, et al. Variation in The risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry. 2010;67(5):497-506.
18. Valenstein M, Kim HM, Ganoczy D, et al. Antidepressant agents and suicide death among US Department of Veterans Affairs patients in depression treatment. J Clin Psychopharmacol. 2012;32(3):346-353.
19. Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs. 2004;18(15):1119-1132. (Pubitemid 40007494)
20. Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry. 1996;37(2):122-124. (Pubitemid 26077588)
21. Hansen L, Wilkinson DG. Drug induced akathisia, suicidal ideation and its treatment in The elderly. Int J Geriatr Psychiatry. 2001;16(2):231-233. (Pubitemid 32166318)
22. Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci. 2003;28(5):331-337. (Pubitemid 37211275)
23. Kasantikul D. Drug-induced akathisia and suicidal tendencies in psychotic patients. J Med Assoc Thai. 1998;81(7):551-554. (Pubitemid 28498400)
24. Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr. Fluoxetine-induced akathisia: clinical an. Theoretical implications. J Clin Psychiatry. 1989;50 (9):339-342. (Pubitemid 19239056)
25. Power AC, Cowen PJ. Fluoxetine and suicidal behaviour: some clinical an. Theoretical aspects of a controversy. Br J Psychiatry. 1992;161:735-741.
26. Teicher MH, Glod CA, Cole JO. Antidepressant drugs an. The emergence of suicidal tendencies. Drug Saf. 1993;8(3):186-212. (Pubitemid 23123065)
27. HamiltonMS, Opler LA. Akathisia, suicidality, and fluoxetine. J Clin Psychiatry. 1992;53(11):401-406.
28. Hansen L. Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia. J Psychopharmacol. 2003;17(4):451-452. (Pubitemid 38076342)
29. AdliM, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? a systematic review. Eur Arch Psychiatry Clin Neurosci. 2005;255(6):387-400. (Pubitemid 43029828)
30. Benkert O, Szegedi A,Wetzel H. Minimum effective dose for antidepressants: an obligatory requirement for antidepressant drug evaluation? Int Clin Psychopharmacol. 1996;11(3):177-185. (Pubitemid 26361790)
31. Dipiro JT, Talbert RL, Matzke GL, Yee GC,Wells BG, PoseyML. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York,NY: McGraw-Hill Medical; 2008.
32. Taylor D, Paton C, Kerwin R. Prescribing Guidelines. 10th ed. London, England: Informa Healthcare; 2010.
33. Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques, 2001. http://www2.sas.com/proceedings/sugi26/p214- 26.pdf. AccessedOctober 1, 2012.
34. VanderWeele TJ. Unmeasured confounding and hazard scales: sensitivity analysis for total, direct, and indirect effects. Eur J Epidemiol. 2013;28 (2):113-117.
35. Vanderweele TJ, Arah OA. Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders. Epidemiology. 2011;22(1):42-52.
36. Healy D. Lines of evidence of The risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom. 2003;72(2):71-79. (Pubitemid 36302475)
37. Maris RW. Suicide. Lancet. 2002;360(9329): 319-326. (Pubitemid 34874728)
38. Nutt DJ. Death and dependence: current controversies ove. The selective serotonin reuptake inhibitors. J Psychopharmacol. 2003;17(4):355-364. (Pubitemid 38076329)
39. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients. The role of akathisia. J Clin Psychiatry. 1991;52(12):491-493.
40. Bech P, Tanghøj P, Andersen HF, Overø K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl). 2002;163 (1):20-25. (Pubitemid 34985308)
41. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry. 1999;174: 297-303. (Pubitemid 29179711)
42. Hansen RA, Moore CG, Dusetzina SB, Leinwand BI, Gartlehner G, Gaynes BN. Controlling for drug dose in systematic review and meta-analysis: a case study of The effect of antidepressant dose. Med Decis Making. 2009;29(1):91-103.
43. KellyMW, Perry PJ, Holstad SG, GarveyMJ. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit. 1989;11(2):165-170. (Pubitemid 19064841)
44. Ruhé HG, Booij J, vWeert HC, et al. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology. 2009;34 (4):999-1010.
45. Ruhé HG, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry. 2006;189:309-316. (Pubitemid 44606743)
46. Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry. 2008;193(1):10-17. (Pubitemid 351946803)
47. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ. 2004;328(7444):879-883. (Pubitemid 38471402)
48. Weiss JJ, Gorman JM. Antidepressant adherence and suicide risk in depressed youth. Am J Psychiatry. 2005;162(9):1756-1757. (Pubitemid 41318255)
49. Smith EG. Association between antidepressant half-life an. The risk of suicidal ideation or behavior among children and adolescents: confirmatory analysis and research implications. J Affect Disord. 2009;114(1-3):143-148.
50. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med. 2002;137(8): 693-695. (Pubitemid 35176104)
51. D'Agostino RB Jr. Propensity scoremethods for bias reduction in The comparison of a treatment to a non-randomized control group. Stat Med. 1998;17 (19):2265-2281. (Pubitemid 28466823)
52. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ. 1997;315(7116): 1151-1154. (Pubitemid 27470317)
53. Piper JM, RayWA, Griffin MR. Effects of Medicaid eligibility expansion on prenatal care and pregnancy outcome in Tennessee. JAMA. 1990;264 (17):2219-2223. (Pubitemid 20382126)
54. Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev. 1990;12:87-107.
55. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information.AmJ Epidemiol. 1995;142(10):1103-1112.
56. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168(3):329-335. (Pubitemid 352019783)